The share price of AIM VACCINE (06660) experienced a significant intraday increase of more than 8%. At the time of writing, the stock was up 7.65% to HK$1.83.

Key Developments and Strategic Moves

The company recently held its 2025 Annual General Meeting, which resulted in a comprehensive reshuffle of its board of directors and various specialized committees. A notable appointment from this restructuring is the promotion of 57-year-old internal R&D veteran Wu Jinan to the roles of Executive President, Chief Scientist, and Chairman of the R&D Management Committee.

Robust Product Pipeline

AIM VACCINE boasts a substantial pipeline with 20 vaccine candidates under development and holds 24 clinical trial approvals. In a significant milestone this January, the company's globally first-developed serum-free next-generation rabies vaccine successfully passed both the on-site inspection for drug clinical trials and the on-site inspection for drug registration production. As there are currently no serum-free rabies vaccines approved for the global market, this product is poised to address a critical market gap upon its eventual launch.

Pursuing a Dual-Listing Structure

Of particular strategic importance, AIM VACCINE announced in late March that its board had reviewed and passed a resolution. The company plans to issue up to 40 million additional domestic shares and intends to list these shares on the National Equities Exchange and Quotations (NEEQ) system, with a further goal of applying for an A-share listing on the Beijing Stock Exchange. The successful execution of this "H+A" dual-listing strategy is expected to not only enhance the company's valuation on the Hong Kong stock market and improve secondary market liquidity but also significantly boost its brand value and accelerate business development.